TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity

TCR/CD3 activation and co-stimulation combined in one T cell retargeting system improve anti-tumor immunity

Cartellieri, M.; Arndt, C.; Feldmann, A.; von Bonin, M.; Ewen, E.-M.; Koristka, S.; Michalk, I.; Stamova, S.; Berndt, N.; Gocht, A.; Bornhäuser, M.; Ehninger, G.; Schmitz, M.; Bachmann, M.

We have recently described a novel modular targeting platform for T cell recruitment that not only efficiently replaces but also is superior to conventional T cell-engaging bispecific antibodies as it allows for the flexible targeting of several antigens and the delivery of co-stimulatory ligands to malignant lesions, thereby enhancing the antitumor potential of redirected T cells.

Keywords: acute myeloid leukemia; CD33; CD137; co-stimulatory ligands; immunotherapy; modular targeting system; single-chain bispecific antibodies; T-cell retargeting

Permalink: https://www.hzdr.de/publications/Publ-20091